Current Pharmaceutical Biotechnology

Editorial [Hot Topic: Relevance of Pharmacokinetics to Antibiotic Dosing in Critically Ill Patients (Guest Editor: Jason A. Roberts)]
pp. 1981-1982(2)
Author: A. Roberts, Jason

Pharmacokinetic Concepts Revisited - Basic and Applied
pp. 1983-1990(8)
Authors: Patel, Kashyap; M.J. Kirkpatrick, Carl

Physiological Changes in the Critically Ill Patient with Sepsis
pp. 1991-1995(5)
Authors: Hosein, Shaun; A. Udy, Andrew; Lipman, Jeffrey

The Relevance of Drug Volume of Distribution in Antibiotic Dosing
pp. 1996-2001(6)
Authors: Ulldemolins, Marta; Rello, Jordi

The Relevance of Drug Clearance to Antibiotic Dosing in Critically Ill Patients
pp. 2002-2014(13)
Author: M. Roberts, Darren

Dosing of Antibiotics in Critically Ill Patients Undergoing Renal Replacement Therapy
pp. 2015-2019(5)
Authors: T. Kielstein, Jan; Burkhardt, Olaf

ARC - Augmented Renal Clearance
pp. 2020-2029(10)
Authors: A. Udy, Andrew; T. Putt, Michael; J. Boots, Robert; Lipman, Jeffrey

The Effect of Critical Illness on Drug Distribution
pp. 2030-2036(7)
Authors: Gonzalez, Daniel; J Conrado, Daniela; Theuretzbacher, Ursula; Derendorf, Hartmut

How to Measure Pharmacokinetics in Critically Ill Patients?
pp. 2037-2043(7)
Authors: Liu, Xin; S. Kruger, Peter; S. Roberts, Michael

Relevance of Pharmacokinetic and Pharmacodynamic Modeling to Clinical Care of Critically Ill Patients
pp. 2044-2061(18)
Authors: B. Bulitta, Jurgen; B. Landersdorfer, Cornelia; Forrest, Alan; V. Brown, Silvia; N. Neely, Michael; T. Tsuji, Brian; Louie, Arnold

Reducing the Development of Antibiotic Resistance in Critical Care Units
pp. 2062-2069(8)
Authors: P.D. Deege, Marjolein; L. Paterson, David

Using PK/PD to Optimize Antibiotic Dosing for Critically Ill Patients
pp. 2070-2079(10)
Author: A. Roberts, Jason

Editorial [Hot Topic: TGF-β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)]
pp. 2080-2080(1)
Author: Schlingensiepen, Karl-Hermann

Structures of TGF-β Receptor Complexes: Implications for Function and Therapeutic Intervention Using Ligand Traps
pp. 2081-2098(18)
Authors: P. Hinck, Andrew; D. O'Connor-McCourt, Maureen

Biology of Transforming Growth Factor-β Signaling
pp. 2099-2107(9)
Authors: Ikushima, Hiroaki; Miyazono, Kohei

TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
pp. 2108-2120(13)
Authors: A. van Meeteren, Laurens; Goumans, Marie-Jose; ten Dijke, Peter

Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
pp. 2121-2137(17)
Authors: T. Buijs, Jeroen; Juarez, Patricia; A. Guise, Theresa

The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
pp. 2138-2149(12)
Authors: C. Connolly, Erin; J. Akhurst, Rosemary

TGF-β2 Signaling in High-Grade Gliomas
pp. 2150-2157(8)
Authors: Hau, Peter; Jachimczak, Piotr; Schlaier, Jurgen; Bogdahn, Ulrich

Transforming Growth Factor Beta in Pancreatic Cancer
pp. 2158-2164(7)
Authors: Hilbig, Andreas; Oettle, Helmut

Role of TGF-β in Melanoma
pp. 2165-2175(11)
Authors: Busse, A.; Keilholz, U.

Antibody Targeting of TGF-β in Cancer Patients
pp. 2176-2189(14)
Authors: Lonning, Scott; Mannick, Joan; M. McPherson, John

TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
pp. 2190-2202(13)
Authors: E. Ling, Leona; Lee, Wen-Cherng

The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2
pp. 2203-2213(11)
Authors: Jaschinski, Frank; Rothhammer, Tanja; Jachimczak, Piotr; Seitz, Christian; Schneider, Anneliese; Schlingensiepen, Karl-Hermann